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We examine the role of big data and machine learning in cancer research. We describe an example in cancer research
where gene-level data from The Cancer Genome Atlas (TCGA) consortium is interpreted using a pathway-level model.
As the complexity of computational models increases, their sample requirements grow exponentially. This growth
stems from the fact that the number of combinations of variables grows exponentially as the number of variables
increases. Thus, a large sample size is needed. The number of variables in a computational model can be reduced by
incorporating biological knowledge. One particularly successful way of doing this is by using available gene regulatory,
signaling, metabolic, or context-specific pathway information. We conclude that the incorporation of existing biological
knowledge is essential for the progress in using big data for cancer research.
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A report on new biology emphasizes the great potential
of biosciences in the areas of health, food, energy, and
environment in the 21st century [1]. The report predicts
that global problems in these areas will be resolved through
scientific integration. Furthermore, the report suggests
that as biology develops into an information-based
science, the key to successful scientific integration lies
in the development of computational methods. These
include support for data integration, model development
for systems biology, and visualization of large masses of
data. The development of these methods inevitably
depends on systematic collection of large amounts of
loosely connected, inherently noisy, and heterogeneous
data, commonly called big data.
The volume, accumulation velocity, and complexity of
biological data have grown beyond any feasible manual
processing scenario, easily fulfilling all criteria for big data.
This ubiquitous term is currently often used to vaguely
describe almost any big data. However, the volume of the
data should not be taken as the sole hallmark of big
data. Modern computers can be scaled up fairly easily* Correspondence: yliharja@cs.tut.fi
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unless otherwise stated.to automate the repeating tasks that are necessary for
analyzing even the largest data collections, assuming that
the structure of the data is known and sufficiently stable.
Instead, the mere complexity of the data can make even
moderate-sized data sets extremely challenging to analyze.
For example, the human genome sequence, while quite
large in size, could be easily processed computationally if
its complexity allowed us to describe how exactly it needs
to be analyzed. Furthermore, emerging new measurement
technologies constantly feed the growth of complexity in
biological data sets. For example, in the Cancer Genome
Atlas (TCGA) project, the principal difficulty arises
from the multitude of data types, not from the data
volume per se [2].Black box approaches can make limited
predictions using big data
Intelligent machine-learning and pattern recognition
algorithms are needed to systematically extract information
from big data. Sometimes the expectation is that algorithms
more or less automatically bring forward interesting and
important information out of a mass of unstructured data.
However, the definitions of “interesting” and “important”
are assessed on a subjective and context-dependent basis,
and the computer can only recognize correlations betweenntral. This is an Open Access article distributed under the terms of the Creative
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unless programmed explicitly. Therefore, such enthusiastic
expectations are not well-founded.
Machine-learning systems, where the core of the
system is deliberately detached from the reality, are
called black-box approaches, and they underline the
irrelevance of the deduction process. The focus of
black-box approaches is correlation-based prediction.
All forms of input data are equally important for this
system, and the core of the system is inaccessible and
uninterpretable for domain experts, such as oncologists. In
a black-box approach, the contribution of the domain
expert is usually focused on preprocessing data and
selecting promising features for further processing.
For example, the self-organizing map (SOM) is an
established black-box method of machine learning
and visualization. Given the topology and convergence
properties, SOM self-organizes and adapts to the input
data. The entire process can be seen as execution of an
optimization algorithm. It is sometimes claimed that SOM
with an adaptive topology could reveal the secrets buried in
the data. However, from the point of view of optimization,
adaptive topology is equivalent to having more free parame-
ters, thus adding to the problem instead of solving it. The
same applies to the deep-learning approach. Unless real-life
meaning is coded by manually preselecting the cost
functions and the topology of the deep-learning
method, the entire process is reduced into observing
correlations between variables unattached from reality.
To conclude, black-box approaches can be used to
make predictions by using big data. However, these
approaches are limited in their capability to shed light
beyond the observed data, namely gaining a system-level
understanding of the mechanisms responsible for the data.
The curse of dimensionality rules out black-box
methods in cancer research
The availability of big data is sometimes expected to lead
to fruitful results in data interpretation by using black-box
methods. However, a leading figure of the machine-learning
community warns against overeager expectations [3].
In cancer research, there is a genuine need to use the
accumulated domain knowledge to cope with limited
sample sizes and the ever-increasing data volumes. As
the complexity of the black-box models, such as SOM
or deep learning, increases, their sample requirements
grow exponentially. This growth stems from the fact that
the number of combinations of variables grows exponen-
tially as the number of variables increases. Thus, a large
sample size is needed to limit the probability of finding a
fitting model by chance alone [3]. As a rule of thumb,
thousands of samples facilitate the inferences made
regarding a handful of variables in general-purpose
black-box models. With millions of variables stemmingfrom contemporary sequencing methods, even the size of
the entire human population is dwarfed by the sample size
requirements. However, in cancer research, the situation
is typically such that the number of samples (usually
number of patients) is relatively small although we
have a large volume of data. Thus, it is necessary to
limit the number of free variables that are inferred,
leading us to consider a modeling approach that builds on
the existing domain knowledge.Mathematical modeling is required for a deeper
understanding
In contrast to black-box approaches, a mathematical
model has better potential to integrate the existing
domain knowledge to the desired extent. Mathemat-
ical models are often used as computational models—
an obvious example being a mathematically defined
group of differential equations for which solutions
can be derived computationally through simulation. A
mathematical model is used in science for a two-fold
purpose: first, to understand and convey understanding of
observed phenomena, and second, to predict the state of a
system given initial conditions [4]. In addition to the
prediction capability, the modeling approach facilitates
an incremental understanding of the domain area
through interpretation of the model parameters. Needless
to say, black-box approaches are usually much more
easily implemented for complex systems because very
little domain knowledge can be implemented into
them.Machine learning and mathematical modeling – two
sides of the same coin
If we accept the view that machine learning is a special
case of mathematical modeling, both can be easily
defined in similar terms. A machine-learning system
includes an internal representation that directly cor-
responds to a mathematical model. The processes of
machine learning and mathematical modeling include
parameter fitting (technically, optimization). Finally, the
goals of machine learning and mathematical modeling
coincide. Both aim to predict outcome based on
measurement data, e.g., patient survival may be predicted
based on clinical observations. Just as importantly, the goal
of machine learning and mathematical modeling is to
gain a broad-level understanding of the subject area
by observing how well different models fit the data.
However, a mathematical model facilitates the accumula-
tion of knowledge into its structure and parameter values.
Instead, a black-box approach has a more predetermined
structure, detached from reality, and its knowledge accu-
mulation capacity is restricted to preprocessing of input
data and preselection of promising features.
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between black-box and modeling approaches using an
example from everyday life.
Example 1. How can big data help fix a radio?
Let us trace the footsteps of the famous article “Can a
biologist fix a radio?” [5]. Assume that we have a set of
transistor radios of which some are broken. Our goal is
to find out how to fix the broken radios using either
a black-box or modeling approach. We base our under-
standing on the measurements of a few properties of
the radios, for example, localized electric potential,
temperature, visual integrity, and acoustic measurements.
Even for a small set of radios, the volume of data can be
overwhelming, e.g., measuring electric potential with a
typical radio frequency of 1 GHz produces one billion
samples per second. When sampling from multiple points
and after adding other measurements, such as temperature,
we can justifiably call our measurement set “big data.”
In the black-box approach, if we do not use any domain
knowledge, we obtain correlations between the mea-
surements and the statuses of the radios. One logical
conclusion might be that heat is required for the
radio to operate if working radios are slightly warmer
than broken radios. It is easy to see that the black-box
approach is not particularly efficient in learning how to fix
the radios. For example, heating radios to the appropriate
temperature does not fix them.
The modeling approach, on the other hand, permits
domain experts to increase our knowledge on the radios.
If we obtain help from electrical engineers, they will
be able to improve the results by restricting the measure-
ments to the sensible ones using their knowledge on radios,
and perhaps they will even include the circuit diagram of
these particular types of radios. We might be able to
concentrate on the electric potential measurements of
suspicious components to detect abnormalities that
might result from a broken wire between the components
or to isolate a faulty component that might cause the radio
to appear broken.
Integration of domain knowledge is required for
machine learning in cancer research
In cancer research, the situation is typically such that
we have a large volume of data, for example, from
genome-wide expression, copy number, or methylation
measurements, but the number of samples is relatively
small. This situation prevents the use of many datum-
mining algorithms, and we end up in a familiar situ-
ation, where genome-wide measurements result in the
identification of one gene or of another feature, such
as a mutation, instead of giving a deeper understanding of
what is occurring in the gene regulatory network of
cancerous cells. Thus, we argue that the inclusion ofdomain knowledge is necessary in limiting the degrees
of freedom to a level where machine learning and big
data can be fully used in cancer research.
One particularly successful way of introducing domain
knowledge to genome-wide data is by using gene regulatory,
signaling, metabolic, or context-specific pathways. These
pathways contain information on genes, in relation to each
other, that often work in concert towards a phenotypic
action, such as cell movement, or something more intan-
gible, such as growth signaling, giving the cell’s interaction a
biological context. If we refer to the previous example,
measurements of genes are much like measurements
of the radio’s components or other properties. They are
ambiguous without context and do not offer much help in
understanding how the entire system works or why it does
not work the way it should. Continuing with the analogy,
pathways give genes a context whereby they influence the
system, much like circuit diagrams show connections of
the components in the radio, an inarguably valuable tool
in understanding and fixing the device.
Pathway activities or inactivity are often more interesting
than individual genes or mutations. This is not only
because different aberrations can bring similar cancer
phenotypes, for example the mouse double minute 2
homolog (MDM2)-p53 interaction, but also because
pathways are closer to the phenotype that is often the
context of interest in cancer research, such as “are the cells
dividing after the treatment or not?” Computationally, the
appealing feature in pathways is that they can reduce the
dimensionality of gene expression data from tens of
thousands of genes to hundreds of pathways. This reduc-
tion also makes genome-wide data much more digestible
for researchers. Therefore, in many applications, re-
searchers rather work on the pathway level than on the
gene level, and many different pathway analyses have been
implemented to date.
Recent genomic and molecular characterizations of
cancer, especially the findings reported by the TCGA
project, have shed light on cancer heterogeneity and
potential targeted therapeutics, for example by recognizing
new subtypes of gastric cancer [6]. In general, targeted
computational methods, which make effective use of the
available multimodal biological information, can sig-
nificantly improve our ability to identify candidate bio-
markers and targets and to conduct functional analyses
[7]. For example, reducing the redundancy in enrichment
analysis helps to reveal gene ontology modules efficiently
and systematically [8].
Example 2. Using pathway-level information connected
with TCGA data
To become malignant cancer cells, normal cells must
acquire a set of mutations that confer “hallmark” traits, such
as increased proliferation, immortality, and invasiveness [9].
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nant growth, but several genes contributing to the process
need to be “hit” before a pivotal phenotypic change takes
place. Acquiring these traits can be conveniently described
and understood as alterations in pathways. In many
settings, cancers are classified based on the status of a
single (often actionable) gene, such as Her2 amplification-
positive breast cancers and KIT mutation-positive
gastrointestinal tumors, but almost all cancers have a
characteristic set of somatic mutations that can be
used to identify and classify the tumors and even to
learn something about their clinical behavior.
After profiling a cohort of tumors, such as in the
TCGA project, the common follow-up analysis is to
cluster the tumors into subgroups based on genomic fea-
tures, such as gene expression. Sometimes the projection
of clinical data on top of the clusters reveals different clin-
ical courses for the patients in each group, but more often,
there is no clear difference in physiology. A similar deduc-
tion can also be conducted beginning from the gene
expression that makes each group different, except that
we do not currently understand the function of many
genes, and even if we do, we do not know how to connect
their molecular functions to the tumor phenotype.
Furthermore, gene expression data can be quite different
for many similar tumors because aberrations in different
genes can cause similar phenotypic effects.
Statistical tools for investigating set enrichment can
reveal hidden trends in gene lists that differ between tumor
subgroups; for example, surprisingly, many radiation
resistance-related genes differentiate one subgroup from
others. The set enrichment tools also have the advantage
of not being very sensitive to noisy gene expression data.
Pathway-level results might hint as to why the clinical
course for these patients might have been different than
others. If enrichment analysis is performed systematically
for hundreds of pathways, those data can be used to profile
each subgroup. Alternatively, if we compute the enriched
pathways for each sample prior to clustering, we can use
the enrichment data to cluster tumors into subgroups that
might be easier to interpret and understand. Pathway
analysis offers intriguing opportunities; for example, if we
know that the pathway activation profiles of two subgroups
of different cancers are similar, we might hypothesize that
both can be treated effectively by the same drug [10].
Conclusions
The bigness of data does not come to the rescue, as the
sample size requirements will always outgrow the number
of available samples. Thus, the blind use of black-box
methods will not be a working solution for analyzing big
data in cancer research. The use of modeling approaches,
which incorporate existing domain knowledge, is essential
for the progress in this field.Competing interests
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